|
1
|
Zhang X, Wang Z, Tian L, Xie J, Zou G and
Jiang F: Increased expression of FGF19 contributes to tumor
progression and cell motility of human thyroid cancer. Otolaryngol
Head Neck Surg. 154:52–58. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kong LL, Man DM, Wang T, Zhang GA and Cui
W: siRNA targeting RBP2 inhibits expression, proliferation,
tumorigenicity and invasion in thyroid carcinoma cells. Oncol Lett.
10:3393–3398. 2015.PubMed/NCBI
|
|
3
|
Ye WC, Gao L, Huang J, Fang XM and Xie G:
Suppressed Krüppel-like factor 17 expression induces tumor
proliferation, metastasis and a poor prognosis in papillary thyroid
carcinoma. Mol Med Rep. 10:2087–2092. 2014.PubMed/NCBI
|
|
4
|
Hatakeyama S: TRIM proteins and cancer.
Nat Rev Cancer. 11:792–804. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Napolitano LM and Meroni G: TRIM family:
Pleiotropy and diversification through homomultimer and
heteromultimer formation. IUBMB Life. 64:64–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cambiaghi V, Giuliani V, Lombardi S,
Marinelli C, Toffalorio F and Pelicci PG: TRIM proteins in cancer.
Adv Exp Med Biol. 770:77–91. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Song X, Fu C, Yang X, Sun D, Zhang X and
Zhang J: Tripartite motif-containing 29 as a novel biomarker in
non-small cell lung cancer. Oncol Lett. 10:2283–2288.
2015.PubMed/NCBI
|
|
8
|
Sun H, Dai X and Han B: TRIM29 as a novel
biomarker in pancreatic adenocarcinoma. Dis Markers.
2014:3178172014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kosaka Y, Inoue H, Ohmachi T, Yokoe T,
Matsumoto T, Mimori K, Tanaka F, Watanabe M and Mori M: Tripartite
motif-containing 29 (TRIM29) is a novel marker for lymph node
metastasis in gastric cancer. Ann Surg Oncol. 14:2543–2549. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu C, Huang X, Hou S, Hu B and Li H:
Silencing of tripartite motif (TRIM) 29 inhibits proliferation and
invasion and increases chemosensitivity to cisplatin in human lung
squamous cancer NCI-H520 cells. Thorac Cancer. 6:31–37. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang T, Tang HM, Lu S, Yan DW, Yang YX
and Peng ZH: Up-regulation of tripartite motif-containing 29
promotes cancer cell proliferation and predicts poor survival in
colorectal cancer. Med Oncol. 30:7152013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ai L, Kim WJ, Alpay M, Tang M, Pardo CE,
Hatakeyama S, May WS, Kladde MP, Heldermon CD, Siegel EM, et al:
TRIM29 suppresses TWIST1 and invasive breast cancer behavior.
Cancer Res. 74:4875–4887. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kanno Y, Watanabe M, Kimura T, Nonomura K,
Tanaka S and Hatakeyama S: TRIM29 as a novel prostate basal cell
marker for diagnosis of prostate cancer. Acta Histochem.
116:708–712. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jin S, Borkhuu O, Bao W and Yang YT:
Signaling pathways in thyroid cancer and their therapeutic
implications. J Clin Med Res. 8:284–296. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang X, Liu G, Xiao H, Yu F, Xiang X, Lu
Y, Li W, Liu X, Li S and Shi Y: TPX2 overexpression in medullary
thyroid carcinoma mediates TT cell proliferation. Pathol Oncol Res.
20:641–648. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Z, Yang L, Teng X, Zhang H and Guan H:
The involvement of CXCR7 in modulating the progression of papillary
thyroid carcinoma. J Surg Res. 191:379–388. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reymond A, Meroni G, Fantozzi A, Merla G,
Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, et
al: The tripartite motif family identifies cell compartments. EMBO
J. 20:2140–2151. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kapp LN, Painter RB, Yu LC, van Loon N, CW
III Richard, James MR, Cox DR and Murnane JP: Cloning of a
candidate gene for ataxia-telangiectasia group D. Am J Hum Genet.
51:45–54. 1992.PubMed/NCBI
|
|
19
|
Tan ST, Liu SY and Wu B: TRIM29
Overexpression promotes proliferation and survival of bladder
cancer cells through NF-κB signaling. Cancer Res Treat.
48:1302–1312. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Masuda Y, Takahashi H, Sato S,
Tomomori-Sato C, Saraf A, Washburn MP, Florens L, Conaway RC,
Conaway JW and Hatakeyama S: TRIM29 regulates the assembly of DNA
repair proteins into damaged chromatin. Nat Commun. 6:72992015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang L, Yang H, Palmbos PL, Ney G, Detzler
TA, Coleman D, Leflein J, Davis M, Zhang M, Tang W, et al:
ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates
radioresistance in pancreatic cancer cells. Cancer Res.
74:1778–1788. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu R, Hu J, Zhang T, Jiang C and Wang HY:
TRIM29 overexpression is associated with poor prognosis and
promotes tumor progression by activating Wnt/β-catenin pathway in
cervical cancer. Oncotarget. 7:28579–28591. 2016.PubMed/NCBI
|
|
23
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuan Z, Villagra A, Peng L, Coppola D,
Glozak M, Sotomayor EM, Chen J, Lane WS and Seto E: The ATDC
(TRIM29) protein binds p53 and antagonizes p53-mediated functions.
Mol Cell Biol. 30:3004–3015. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: The cell cycle: A review of regulation, deregulation
and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Malumbres M: Cyclins and related kinases
in cancer cells. J BUON. 12 Suppl 1:S45–S52. 2007.PubMed/NCBI
|
|
27
|
Deryugina EI and Quigley JP: Tumor
angiogenesis: MMP-mediated induction of intravasation- and
metastasis-sustaining neovasculature. Matrix Biol. 44–46, 94–112.
2015.
|
|
28
|
Yoon SO, Park SJ, Yun CH and Chung AS:
Roles of matrix metalloproteinases in tumor metastasis and
angiogenesis. J Biochem Mol Biol. 36:128–137. 2003.PubMed/NCBI
|
|
29
|
Abarikwu SO and Farombi EO: Atrazine
induces apoptosis of SH-SY5Y human neuroblastoma cells via the
regulation of Bax/Bcl-2 ratio and caspase-3-dependent pathway.
Pestic Biochem Physiol. 118:90–98. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hsieh AC, Truitt ML and Ruggero D:
Oncogenic AKTivation of translation as a therapeutic target. Br J
Cancer. 105:329–336. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ávalos Y, Canales J, Bravo-Sagua R,
Criollo A, Lavandero S and Quest AF: Tumor suppression and
promotion by autophagy. BioMed Res Int. 2014:6039802014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xing M: Genetic alterations in the
phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
Thyroid. 20:697–706. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou XM, Sun R, Luo DH, Sun J, Zhang MY,
Wang MH, Yang Y, Wang HY and Mai SJ: Upregulated TRIM29 promotes
proliferation and metastasis of nasopharyngeal carcinoma via
PTEN/AKT/mTOR signal pathway. Oncotarget. 7:13634–13650.
2016.PubMed/NCBI
|
|
34
|
Brzezianska E and Pastuszak-Lewandoska D:
A minireview: The role of MAPK/ERK and PI3K/Akt pathways in thyroid
follicular cell-derived neoplasm. Front Biosci (Landmark Ed).
16:422–439. 2011. View
Article : Google Scholar : PubMed/NCBI
|
